Akari Therapeutics raises ~$5.5M via private placement of ADSs and warrants

Akari Therapeutics Plc

Gross proceeds of ~$5.5M from 1,470,588 ADSs at $3.74 per unit; three closings through July 15, 2026.
Each unit includes one ADS (or pre-funded warrant) plus Series H/I/J warrants exercisable at $3.74 per ADS.
Warrants require shareholder approval; pre-funded warrants exercisable immediately.
Net proceeds for working capital and general corporate purposes; Paulson Investment paid 2% cash fee plus 117,647 ADSs.
Offering exempt from registration under Section 4(a)(2) and Regulation D.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Akari Therapeutics Plc entered into Purchase Agreement with certain investors valued at approximately $5.5 million (effective 2026-05-20).

Action: entry
Agreement: equity purchase
Counterparty: certain investors
Value: approximately $5.5 million
Effective: 2026-05-20

Exact text from the filing

On May 20, 2026, Akari Therapeutics, Plc (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain investors

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Akari Therapeutics Plc filing history →

Source: SEC EDGAR

accession 0001493152-26-025037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.